ADVERTISEMENT

Cipla - Regulatory Set Back; U.S. Scale Up Gets Delayed: Prabhudas Lilladher

FDA recently highlighted eight observations in the 483 letters issued to Cipla’s Pithampur (Indore) unit.

<div class="paragraphs"><p>(Source: Ivan Traimak/freepik)</p></div>
(Source: Ivan Traimak/freepik)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.  
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit